Secondary Logo

Journal Logo

Most Popular Articles

Potent, Selective CARs as Potential T-Cell Therapeutics for HPV-positive Cancers

Wang, Xueyin; Sandberg, Mark L.; Martin, Aaron D.; More

Journal of Immunotherapy. 44(8):292-306, October 2021.

Antitumor Potency of an Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, Lisocabtagene Maraleucel in Combination With Ibrutinib or Acalabrutinib

Qin, Jim S.; Johnstone, Timothy G.; Baturevych, Alex; More

Journal of Immunotherapy. 43(4):107-120, May 2020.

Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment

Diem, Stefan; Fässler, Mirjam; Bomze, David; More

Journal of Immunotherapy. 42(3):89-93, April 2019.

Generation of Antitumor T Cells For Adoptive Cell Therapy With Artificial Antigen Presenting Cells

Shrestha, Bishwas; Zhang, Yongliang; Yu, Bin; More

Journal of Immunotherapy. 43(3):79-88, April 2020.

Association Between Body Mass Index and Survival Outcomes In Patients Treated With Immune Checkpoint Inhibitors: Meta-analyses of Individual Patient Data

Nie, Run-Cong; Chen, Guo-Ming; Wang, Yun; More

Journal of Immunotherapy. 44(9):371-375, November/December 2021.

Messenger RNA-based Vaccines With Dual Activity Induce Balanced TLR-7 Dependent Adaptive Immune Responses and Provide Antitumor Activity

Fotin-Mleczek, Mariola; Duchardt, Katharina M.; Lorenz, Christina; More

Journal of Immunotherapy. 34(1):1-15, January 2011.

Rapid Identification and Evaluation of Neoantigen-reactive T-Cell Receptors From Single Cells

Paria, Biman C.; Levin, Noam; Lowery, Frank J.; More

Journal of Immunotherapy. 44(1):1-8, January 2021.

CD19 Isoforms Enabling Resistance to CART-19 Immunotherapy Are Expressed in B-ALL Patients at Initial Diagnosis

Fischer, Jeannette; Paret, Claudia; El Malki, Khalifa; More

Journal of Immunotherapy. 40(5):187-195, June 2017.

A Clinical Development Paradigm for Cancer Vaccines and Related Biologics

Hoos, Axel; Parmiani, Giorgio; Hege, Kristen; More

Journal of Immunotherapy. 30(1):1-15, January 2007.

The Role of Extracellular Spacer Regions in the Optimal Design of Chimeric Immune Receptors: Evaluation of Four Different scFvs and Antigens

Guest, Ryan D; Hawkins, Robert E; Kirillova, Natalia; More

Journal of Immunotherapy. 28(3):203-211, May-June 2005.

Immune-related Adverse Events of Dendritic Cell Vaccination Correlate With Immunologic and Clinical Outcome in Stage III and IV Melanoma Patients

Boudewijns, Steve; Westdorp, Harm; Koornstra, Rutger H.T.; More

Journal of Immunotherapy. 39(6):241-248, July/August 2016.

Immune-related Adverse Events and Survival in Solid Tumors Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis

Petrelli, Fausto; Grizzi, Giulia; Ghidini, Michele; More

Journal of Immunotherapy. 43(1):1-7, January 2020.

Zoledronate Sensitizes Neuroblastoma-derived Tumor-initiating Cells to Cytolysis Mediated by Human γδ T Cells

Nishio, Nobuhiro; Fujita, Mitsugu; Tanaka, Yoshimasa; More

Journal of Immunotherapy. 35(8):598-606, October 2012.

Chimeric Antigen Receptor–modified T Cells Repressed Solid Tumors and Their Relapse in an Established Patient-derived Colon Carcinoma Xenograft Model

Teng, Ruidi; Zhao, Jingjing; Zhao, Yiding; More

Journal of Immunotherapy. 42(2):33-42, February/March 2019.

Long-term Overall Survival and Predictors in Anti–PD-1-naive Melanoma Patients With Brain Metastases Treated With Immune Checkpoint Inhibitors in the Real-world Setting: A Multicohort Study

Naik, Girish S.; Buchbinder, Elizabeth I.; Cohen, Justine V.; More

Journal of Immunotherapy. 44(8):307-318, October 2021.

Engineering NK Cells Modified With an EGFRvIII-specific Chimeric Antigen Receptor to Overexpress CXCR4 Improves Immunotherapy of CXCL12/SDF-1α-secreting Glioblastoma

Müller, Nadja; Michen, Susanne; Tietze, Stefanie; More

Journal of Immunotherapy. 38(5):197-210, June 2015.

Identification of a Promiscuous Epitope Peptide Derived From HSP70

Matsui, Hiroto; Hazama, Shoichi; Tamada, Koji; More

Journal of Immunotherapy. 42(7):244-250, September 2019.

Efficacy and Safety of Pembrolizumab in Patients Enrolled in KEYNOTE-030 in the United States: An Expanded Access Program

Gangadhar, Tara C.; Hwu, Wen-Jen; Postow, Michael A.; More

Journal of Immunotherapy. 40(9):334-340, November/December 2017.

Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class

Brischwein, Klaus; Parr, Larissa; Pflanz, Stefan; More

Journal of Immunotherapy. 30(8):798-807, November-December 2007.

The Lewis-Y Carbohydrate Antigen is Expressed by Many Human Tumors and Can Serve as a Target for Genetically Redirected T cells Despite the Presence of Soluble Antigen in Serum

Westwood, Jennifer A.; Murray, William K.; Trivett, Melanie; More

Journal of Immunotherapy. 32(3):292-301, April 2009.

PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors

Soares, Kevin C.; Rucki, Agnieszka A.; Wu, Annie A.; More

Journal of Immunotherapy. 38(1):1-11, January 2015.

PD-1 Blockade Augments Th1 and Th17 and Suppresses Th2 Responses in Peripheral Blood From Patients With Prostate and Advanced Melanoma Cancer

Dulos, John; Carven, Gregory J.; van Boxtel, Susan J.; More

Journal of Immunotherapy. 35(2):169-178, February-March 2012.

Establishment and Large-scale Expansion of Minimally cultured “Young” Tumor Infiltrating Lymphocytes for Adoptive Transfer Therapy

Itzhaki, Orit; Hovav, Einat; Ziporen, Yaara; More

Journal of Immunotherapy. 34(2):212-220, March 2011.

Immune Checkpoint Inhibitor–associated Diarrhea and Colitis: A Systematic Review and Meta-analysis of Observational Studies

Tran, Ashley N.; Wang, Melinda; Hundt, Melanie; More

Journal of Immunotherapy. 44(8):325-334, October 2021.

Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy

Morgan, Richard A.; Chinnasamy, Nachimuthu; Abate-Daga, Daniel; More

Journal of Immunotherapy. 36(2):133-151, February-March 2013.

Application of a MABEL Approach for a T-Cell-Bispecific Monoclonal Antibody: CEA TCB

Dudal, Sherri; Hinton, Heather; Giusti, Anna M.; More

Journal of Immunotherapy. 39(7):279-289, September 2016.

Potent Control of Tumor Growth by CEA/CD3-bispecific Single-chain Antibody Constructs That Are Not Competitively Inhibited by Soluble CEA

Lutterbuese, Ralf; Raum, Tobias; Kischel, Roman; More

Journal of Immunotherapy. 32(4):341-352, May 2009.

Cancer Therapeutics–related Cardiac Dysfunction in Patients Treated With Immune Checkpoint Inhibitors: An Understudied Manifestation

Peleg Hasson, Shira; Arnold, Joshua; Merdler, Ilan; More

Journal of Immunotherapy. 44(5):179-184, June 2021.

Bullous Pemphigoid–like Skin Lesions and Overt Eosinophilia in a Patient With Melanoma Treated With Nivolumab: Case Report and Review of the Literature

Anastasopoulou, Amalia; Papaxoinis, Georgios; Diamantopoulos, Panagiotis; More

Journal of Immunotherapy. 41(3):164-167, April 2018.

Hemofiltration Successfully Eliminates Severe Cytokine Release Syndrome Following CD19 CAR-T-Cell Therapy

Liu, Yanfen; Chen, Xinfeng; Wang, Dao; More

Journal of Immunotherapy. 41(9):406-410, November/December 2018.

A Phase I Study of an IDO-1 Inhibitor (LY3381916) as Monotherapy and in Combination With an Anti-PD-L1 Antibody (LY3300054) in Patients With Advanced Cancer

Kotecki, Nuria; Vuagnat, Perrine; O’Neil, Bert H.; More

Journal of Immunotherapy. 44(7):264-275, September 2021.

Evaluating for Pseudoprogression in Colorectal and Pancreatic Tumors Treated With Immunotherapy

Parseghian, Christine M.; Patnana, Madhavi; Bhosale, Priya; More

Journal of Immunotherapy. 41(6):284-291, July/August 2018.

Pilot Trial of Adoptive Transfer of Chimeric Antigen Receptor–transduced T Cells Targeting EGFRvIII in Patients With Glioblastoma

Goff, Stephanie L.; Morgan, Richard A.; Yang, James C.; More

Journal of Immunotherapy. 42(4):126-135, May 2019.

Real-world Outcomes of First-line Anti-PD-1 Therapy for Advanced Melanoma: A Nationwide Population-based Study

van Zeijl, Michiel C.T.; Haanen, John B.A.G.; Wouters, Michel W.J.M.; More

Journal of Immunotherapy. 43(8):256-264, October 2020.

First-in-Human Treatment With a Dendritic Cell-targeting Lentiviral Vector-expressing NY-ESO-1, LV305, Induces Deep, Durable Response in Refractory Metastatic Synovial Sarcoma Patient

Pollack, Seth M.; Lu, Hailing; Gnjatic, Sacha; More

Journal of Immunotherapy. 40(8):302-306, October 2017.

Treatment With Tumor-infiltrating Lymphocytes in Advanced Melanoma: Evaluation of Early Clinical Implementation of an Advanced Therapy Medicinal Product

Lindenberg, Melanie A.; Retèl, Valesca P.; van den Berg, Joost H.; More

Journal of Immunotherapy. 41(9):413-425, November/December 2018.

Wilms Tumor Gene (WT1) Peptide–based Cancer Vaccine Combined With Gemcitabine for Patients With Advanced Pancreatic Cancer

Nishida, Sumiyuki; Koido, Shigeo; Takeda, Yutaka; More

Journal of Immunotherapy. 37(2):105-114, February/March 2014.

Chimeric Antigen Receptor-modified Donor Lymphocyte Infusion Improves the Survival of Acute Lymphoblastic Leukemia Patients With Relapsed Diseases After Allogeneic Hematopoietic Stem Cell Transplantation

Wang, Tao; Gao, Lei; Hu, Xiaoxia; More

Journal of Immunotherapy. 42(3):81-88, April 2019.

DNA Vaccine Encoding HPV16 Oncogenes E6 and E7 Induces Potent Cell-mediated and Humoral Immunity Which Protects in Tumor Challenge and Drives E7-expressing Skin Graft Rejection

Chandra, Janin; Dutton, Julie L.; Li, Bo; More

Journal of Immunotherapy. 40(2):62-70, February/March 2017.

Vaccination of Metastatic Colorectal Cancer Patients With Matured Dendritic Cells Loaded With Multiple Major Histocompatibility Complex Class I Peptides

Kavanagh, Brian; Ko, Andrew; Venook, Alan; More

Journal of Immunotherapy. 30(7):762-772, October 2007.

Show: